Overview
Stomach adenocarcinoma, also called gastric adenocarcinoma or stomach cancer, is a type of cancer that starts in the cells lining the inside of the stomach. It is the most common form of stomach cancer, making up about 90-95% of all stomach cancers. The cancer begins when normal stomach lining cells grow out of control and form a tumor. Over time, the tumor can grow through the stomach wall and spread to nearby organs, lymph nodes, or other parts of the body. In the early stages, stomach adenocarcinoma often causes no symptoms at all, which makes it hard to catch early. As the cancer grows, people may notice stomach pain or discomfort, feeling full quickly after eating, nausea, unexplained weight loss, or difficulty swallowing. Some people develop bleeding in the stomach, which can cause dark or tarry stools or vomiting blood. Treatment depends on how advanced the cancer is. Options include surgery to remove part or all of the stomach, chemotherapy, radiation therapy, targeted drug therapies, and immunotherapy. When caught early, the cancer can sometimes be cured. Unfortunately, many cases are found at a later stage, when treatment focuses on controlling the cancer and improving quality of life. Research into new treatments is ongoing, and options have improved significantly in recent years.
Also known as:
Key symptoms:
Stomach pain or discomfort, especially in the upper abdomenFeeling full very quickly after eating only a small amountUnexplained weight lossNausea or vomitingLoss of appetiteDifficulty swallowingHeartburn or indigestion that does not go awayBloating after mealsDark, tarry, or bloody stoolsVomiting blood or material that looks like coffee groundsFatigue and weaknessSwelling or fluid buildup in the abdomenAnemia (low red blood cell count) causing tiredness and paleness
Multifactorial
Caused by a mix of several genes and environmental factors
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
10 eventsQilu Pharmaceutical Co., Ltd. — PHASE1, PHASE2
AstraZeneca — PHASE3
Dong-A ST Co., Ltd. — PHASE1
Blokhin's Russian Cancer Research Center
Shanghai Zhongshan Hospital — PHASE2
Eikon Therapeutics — PHASE1, PHASE2
Nantes University Hospital — NA
Imperial College London
Massachusetts General Hospital — PHASE2
Jiangsu HengRui Medicine Co., Ltd. — PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableVyloy
in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth …
in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test
Specialists
View all specialists →No specialists are currently listed for NON RARE IN EUROPE: Adenocarcinoma of stomach.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to NON RARE IN EUROPE: Adenocarcinoma of stomach.
Community
No community posts yet. Be the first to share your experience with NON RARE IN EUROPE: Adenocarcinoma of stomach.
Start the conversation →Latest news about NON RARE IN EUROPE: Adenocarcinoma of stomach
No recent news articles for NON RARE IN EUROPE: Adenocarcinoma of stomach.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What stage is my cancer, and what does that mean for my treatment options and outlook?,Has my tumor been tested for HER2, PD-L1, and microsatellite instability, and how do those results affect my treatment?,Should I consider genetic testing to see if my cancer is linked to a hereditary condition, and should my family members be tested?,What are the goals of my treatment — is it aimed at curing the cancer or controlling it?,What clinical trials are available for my type and stage of stomach cancer?,What changes do I need to make to my diet, and should I see a dietitian?,What support services are available to help me and my family cope with this diagnosis?
Common questions about NON RARE IN EUROPE: Adenocarcinoma of stomach
What is NON RARE IN EUROPE: Adenocarcinoma of stomach?
Stomach adenocarcinoma, also called gastric adenocarcinoma or stomach cancer, is a type of cancer that starts in the cells lining the inside of the stomach. It is the most common form of stomach cancer, making up about 90-95% of all stomach cancers. The cancer begins when normal stomach lining cells grow out of control and form a tumor. Over time, the tumor can grow through the stomach wall and spread to nearby organs, lymph nodes, or other parts of the body. In the early stages, stomach adenocarcinoma often causes no symptoms at all, which makes it hard to catch early. As the cancer grows, p
How is NON RARE IN EUROPE: Adenocarcinoma of stomach inherited?
NON RARE IN EUROPE: Adenocarcinoma of stomach follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does NON RARE IN EUROPE: Adenocarcinoma of stomach typically begin?
Typical onset of NON RARE IN EUROPE: Adenocarcinoma of stomach is adult. Age of onset can vary across affected individuals.
Are there clinical trials for NON RARE IN EUROPE: Adenocarcinoma of stomach?
Yes — 20 recruiting clinical trials are currently listed for NON RARE IN EUROPE: Adenocarcinoma of stomach on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.